Theravance Biopharma (TBPH) Net Income towards Common Stockholders (2013 - 2026)
Theravance Biopharma (TBPH) reported Net Income towards Common Stockholders of -$5.0 million for Q1 2026, up 63.4% year-over-year from -$3.0 million in Q1 2025, and up 91.56% quarter-over-quarter from -$58.9 million in Q4 2025.
Theravance Biopharma (TBPH) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$5.0 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$5.0 million, up 63.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 71.9% YoY), and the FY2025 annual result was -$14.0 million, up 19.29% from the prior year.
- Net Income towards Common Stockholders rose to -$5.0 million in Q1 2026 per TBPH's latest filing, from -$58.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $927.1 million in Q3 2022 and troughed at -$58.9 million in Q4 2025.
- A 5-year average of $51.4 million and a median of -$8.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 4400.0% in 2022, then slumped 350.31% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $3.9 million in 2022, then tumbled by 317.93% to -$8.5 million in 2023, then jumped by 377.26% to $23.5 million in 2024, then tumbled by 350.31% to -$58.9 million in 2025, then jumped by 91.56% to -$5.0 million in 2026.
- Business Quant data shows TBPH's Net Income towards Common Stockholders at -$5.0 million in Q1 2026, -$58.9 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Theravance Biopharma | 839.69 Mn | 445.03 Mn | - | -4.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -58.89 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | 23.53 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -8.49 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | 3.89 Mn |
| Sep 30, 2022 | 927.09 Mn |
| Jun 30, 2022 | 18.38 Mn |
| Mar 31, 2022 | 15.59 Mn |
| Dec 31, 2021 | 25.78 Mn |
| Sep 30, 2021 | 20.60 Mn |
| Jun 30, 2021 | 12.45 Mn |